Vaginal Heat Wash-out (HWO) in 4 Groups of Women (Pre- and Postmenopausal With and Without Female Sexual Arousal Disorder (FSAD)).
Phase 1
Completed
- Conditions
- Sexual Dysfunction, Physiological
- Interventions
- Device: Vaginal Heat Wash-Out Device
- Registration Number
- NCT00443248
- Lead Sponsor
- Pfizer
- Brief Summary
The Pfizer developed Heat Wash-Out (HWO) system is a software controlled electromechanical system designed to measure vaginal wall blood flow. A small vaginal probe is attached to a control unit. Output data are collected on a PC. By measuring the clearance of heat from the heated probe, a direct measure of absolute blood flow can be obtained. The study will assess the technique's ability to differentiate between pre- and post-menopausal women; with and without Female Sexual Arousal Disorder (FSAD).
- Detailed Description
Medical Device Development
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 64
Inclusion Criteria
- Pre-menopausal women aged 18-40 (with and without FSAD) or
- Post-menopausal women aged 50-65 (with and without FSAD.
- FSAD must have been present for at least 6 months.
Read More
Exclusion Criteria
- Pregnant or lactating women (pre-menopausal population)
- Systemic Hormone Replacement Therapy (HRT) or Selective Estrogen Receptor Modulator (SERM) (postmenopausal population)
- Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic disease or other major psychological or sexual disorder.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Vaginal Heat Wash-Out Device Vaginal Heat Wash-Out Device -
- Primary Outcome Measures
Name Time Method To assess the safety and toleration of the heat washout device. 2 weeks To investigate differences in vaginal blood flow following visual sexual stimulation in pre-menopausal women with and without FSAD. 2 weeks
- Secondary Outcome Measures
Name Time Method To investigate changes in subjective acute sexual arousal following visual sexual stimulation in women with and without FSAD. 2 weeks
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇦🇺Nedlands, Western Australia, Australia